dr. govindan on the potential for alectinib
Published 9 years ago • 1K plays • Length 2:45Download video MP4
Download video MP3
Similar videos
-
1:42
dr. velcheti on potential of alectinib in frontline alk-positive nsclc
-
0:52
dr. stinchcombe on the benefit of alectinib in alk nsclc
-
3:55
govindan discusses the phase i results of amg 510 evaluated in nsclc
-
0:48
dr. govindan on the future of egfr-mutant nsclc
-
1:09
dr. govindan on genomic characterization of large-cell neuroendocrine lung tumors
-
7:34
what’s on the horizon for immunotherapy in nsclc?
-
1:40
dr. ou on alectinib as treatment for nsclc
-
1:27
dr. neal debates whether alectinib will become the standard frontline thera for alk nsclc
-
7:13
alectinib for relapsed/refractory alk nsclc
-
3:59
alectinib in alk-mutated nsclc
-
2:26
dr. shaw on alectinib as first-line therapy in lung cancer
-
1:17
dr. christina baik on alectinib versus crizotinib in alk-positive lung cancer
-
0:56
nautika1: safety and tolerability of neoadjuvant alectinib in alk-positive nsclc
-
1:12
dr. christina baik on alectinib in patients with alk-lung cancer
-
0:41
dr. gandhi discusses the role of alectinib in alk lung cancer
-
4:00
alectinib eclipses crizotnib for alk positive lung cancer
-
1:01:56
dr shohbit baijal “alectinib or brigatinib – that is the question”
-
0:55
dr. west on fda approval of frontline alectinib in alk nsclc
-
4:23
alecensa: targeted therapy for alk-positive lung cancer